Over the past several years, management has initiated discussions with potential strategic collaborators to provide the resources to advance PRP into clini...
New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, Texas Enrolment now open to patient...
Crowell & Moring International is joining forces with Roche, TogetHER for Health, CAPED and Jhpiego to raise awareness about the surge of br...
87% of respondents deemed mRNA a key modality for the future More than 60% of vaccine makers surveyed plan revamp or new facilities for mRNA manufacturi...
Next&Bio has teamed up with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to establish ...
The first diagnostic test for long COVID is now available to patients across Australia. The test can help physicians diagnose long COVID by differentiating...
During the conference’s poster session, OliX revealed preclinical study results of OLX702A, addressing key mechanisms involved in NASH and obesity. T...
The collaboration agreement combines Angelini Pharma’s expertise in neurological diseases with JCR Pharmaceuticals’ scientific and technologi...
On March 31, 2023, the government of the Hong Kong Special Administrative Region announced that, from April 20, high-risk groups will be able to receive fr...
“We are thrilled to have established a partnership with Dr. Reddy’s while toripalimab’s global commercial network has been steadily expan...
SomaLogic, Inc., a global leader in proteomics technology, announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore. T...
"The Future of Robotic Surgery," over 400 medical specialists gathered to participate in a dynamic exchange of ideas and insights. The ...
EG1206A is a biosimilar drug of the second-generation HER2-positive antibody drug Perjeta® (pertuzumab). EG1206A has a unique binding mechanism for HER...
PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Austr...
© 2024 Biopharma Boardroom. All Rights Reserved.
